At a glance
ClinicalIndex Comparison RecordEarly Ph 1Active· 20 target
Drug / intervention
Memantine XR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Memantine for Enhanced Stroke Recovery
In Brief
A Early Phase 1 clinical trial evaluating Memantine XR and Placebo (for memantine) for Ischemic Stroke and Upper Extremity Weakness. Active but no longer recruiting, targeting 20 participants across 1 site.
Detailed Summary
This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Upper Extremity Weakness
CountriesUnited States
Collaborators--
Timeline
Early Ph 1Active
20142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2014
First PostedMay 2014
TodayJul 2026
Primary CompletionDec 2026
First PostedMay 22, 2014
Enrollment StartJan 1, 2014
Primary CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 12.9 yearsPosted 12.1 years agoPrimary completion in 5 months
Interventions
Memantine XRdrug
The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
Placebo (for memantine)drug
Placebo to be capsuled to look identical to active drug (memantine)